a new glycemic control chioce:Fogtaliptine Benzoate Tablets

  Recently, a new glycemic control medicine, fotagliptine Benzoate Tablets , has been approved for marketing, bringing a new choice of medication for patients with type 2 diabetes. fotagliptine benzoate tablets  is a dipeptidyl peptidase-4 (DPP-4) inhibitor, DPP-4 inhibitor is one of the commonly used drugs for the treatment of type 2 diabetes mellitus, which has a lot of advantages, such as: oral, before and after meals; does not increase the risk of hypoglycemia, less gastrointestinal side effects; does not increase the incidence of cardiovascular events, safety and good tolerability, and so on many other advantages. Sinemetin (fotagliptine benzoate tablets) is used to improve glycemic control in adults with type 2 diabetes mellitus (including monotherapy, as well as combination therapy when metformin hydrochloride alone is not effective in controlling blood glucose).

  Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disease, and the main classes of symptomatic drugs currently used for type 2 diabetes include the following:

  1.Metformin: a first-line therapeutic agent that lowers blood glucose by reducing hepatic glucose output and improving peripheral insulin resistance. It is indicated for patients without contraindications and should always be retained in the treatment regimen.

  2. Sulfonylureas: are insulinotropic agents and include glibenclamide, glipizide, glimepiride, glimepiride, gliquidone and gliclazide. They are divided into short-acting preparations and medium- and long-acting preparations, which are suitable for patients with predominantly elevated postprandial blood glucose or those with high fasting and postprandial blood glucose.

  3. Glargine: It is also an insulinotropic agent, including Repaglinide and Naglinide, which is used for controlling postprandial blood glucose, and also has a certain effect of lowering fasting blood glucose.

  4. α-glucosidase inhibitors: including acarbose, voglibose and miglitol, mainly lowering postprandial blood glucose.

  5. Thiazolidinediones: reduce blood glucose by increasing the sensitivity of target cells to insulin action, including rosiglitazone and pioglitazone.

  6. Sodium glucose co-transporter protein 2 inhibitors (SGLT2 inhibitors): inhibit renal reabsorption of glucose, lowering the renal glucose threshold, thereby promoting urinary glucose excretion. Marketed SGLT2 inhibitors include dagliflozin, empagliflozin, cagliflozin and etogliflozin.

  7. GLP-1 receptor agonist: It can stimulate insulin secretion and inhibit glucagon secretion by activating GLP-1 receptor in a glucose concentration-dependent manner, meanwhile, it can increase glucose uptake in muscle and adipose tissue and inhibit glucose production in liver to play the role of glucose-lowering, and it can also inhibit gastric emptying and suppress appetite. The GLP-1RA listed in China is divided into short-acting and long-acting preparations according to pharmacokinetics.

  8. Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors): reduce the inactivation of GLP-1 in vivo by inhibiting DPP-4 enzyme, so that the endogenous GLP-1 level increases and reduces blood glucose. Domestically marketed drugs in this category include selegiline, saxagliptin, vigliptin, riligiline and alogliptin.

  When choosing drugs for patients with type 2 diabetes mellitus, it is necessary to consider the mechanism of action of the drug and the patient‘s specific situation including the patient‘s body weight, renal function status, whether it contains cardiovascular disease and many other factors.

  In addition to conventional drug therapy, patients with type 2 diabetes need to be supplemented with diet and exercise to achieve the goal of glycemic control.

  SZEB more than a decade to focus on drug impurity , advantageous supply Sitagliptin, Vildagliptin  Dapagliflozin and other drug impurity , for the majority of enterprise and researchers to provide one-stop solution for drug impurity control. For more detailed information, please visit our official website : www.ex-biotech.com or contact us by phone: 0755-23051186, E-mail: sales@ex-biotech.com. We are willing to serve you!